Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 19, 2024 4:46pm
132 Views
Post# 36096708

RE:RE:expiration of options

RE:RE:expiration of optionsYet another end-of- day support.
I have lost count. First there were enough, that I noticed & made note of it on here.
so far, since my first notice 3/3 end of day supports.
there were ample before thst. Just can't give an exact number.
My original notice was in response to " no share activity indicating a buyout or partership"
My point, then & now?
back pre A.N. Deal the price activity was almost identical to now.
Very low volume. Near bottom low pricing, Yet, constant end of day support.
Coincidence?
well wre are at least 6/6 trading days.
S.P. In general?
right now, considering the upside prospects, silly low right now.
The expected updates will be great catalyst to move the price.
end game, a total buyout.
significantly higher than any prices we have seen in many months.
ironically the traders will come & go throughout that rise.
being the case with a decent partnership, license agreement.
A total buyout, Asside from shareholders vote, little would change from the offered price.
one scinario would be competitive bids.
First step, FDA report.
hypothetically it is possible , mutiple deals are in negotiations. With final details being blank, pending the FDA trial parameters.
Using an anlgy?
people can put in a conditional offer on a house , pending a formal inspection report.
being dates, price etc.
None of that information would be public.
After the report, based on findings, there may be minor adjustments to the price.
only once all details are signed off does the deal become public.
Same story. Could ( might) be going on with Onc.
The FDA report will be the first step. The additional steps could be not  far after.
Those forgetting, or not knowing.
Onc approached FDA for a meeting to discuss MBc inclusion details.
ONCs web site says Gobblet & specifically MBc involves Roche & CGAR.
The MBc says TBD.
enjoy the rest iof the night.




<< Previous
Bullboard Posts
Next >>